Not yet recruitingPriority 4 · Lower priorityNCT06963632
A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma
Plain-language summary
This trial is evaluating a new treatment as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
- Drugs / treatments
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details